Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Nat Rev Nephrol. 2018 Aug;14(8):473-474. doi: 10.1038/s41581-018-0028-0.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors offer attractive metabolic and cardiorenal benefits for patients with type 2 diabetes, but are associated with a number of safety issues. A recent study documented that SGTL2 inhibition indirectly triggers the FGF23/1,25-dihydroxyvitamin D/parathyroid hormone axis, which may contribute to adverse effects on bone health.
钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂为 2 型糖尿病患者提供了有吸引力的代谢和心肾益处，但与许多安全问题相关。最近的一项研究表明，SGTL2 抑制间接触发了 FGF23/1,25-二羟维生素 D/甲状旁腺激素轴，这可能导致对骨骼健康的不良影响。
